Company Overview and News

25
E&P 'Bottom Of The Barrel' Club #18-5: Ex-Chapter 11 Company Stats For The First Half Of 2018

2018-09-17 seekingalpha
They're baaack! Actually, some of them have been back for a while, but I have not felt compelled to write about them until now. "They" are, of course, former members of my Bottom of the Barrel Club who declared bankruptcy during the past 2-3 years. The companies in this article are now trading publicly again (with 1 or 2 exceptions). I may refer to them as the "X-11 Club" occasionally.
ECR CHPE UPL GDPMQ LNGG SDRPQ DVN PVA GDAOQ VNR CHAP VNRBP GDRRQ LINEQ TALO GDPM BRMR PVAYQ VNRR HKRCP SBOW SD GDUEQ SDOCQ GDANQ GDP RVRA PVAC SGY HK MPO VNRAP TTEN MPOYQ VNRCP UPLMQ BRY GDPAN SDRXP LINE SDRXQ GDPAQ

153
Stocks To Watch: Alibaba, Target And Energy Plays To Center Stage

2018-08-18 seekingalpha - 3
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
FOCS PDD LGCYP LGCYO QEP TJX EL AVGO ABBV FTNT KLXI CORR ESES SDPI TENB LNR RRS WPX FSBW ESTE NPTN ERF BABA SDCJF PAY MSFT GPS MPOYQ HRS FL MLM BLCN MOS SEA CLPS LB CLB ROSEU DBX CF CRDAF KSS CRDAD CI SSI JAG ROSE SNDE DAVA SJM UNT HUM EOG BHI RGRYY MU LGCY SBUX MNK WRD LOW JKS TOL LONE ERF CLB FTK AMAT CRD KEG KEGX SOXX STT FSWB WLL AQST SM LBRT BV LLEX ADIL NBR RGRLF CMG RRC INTU HIMX BJRI EDUC BE MPO ABBV BA ESRX ECR JG NDLS WPXP MTB RRL VMW ALRM LQDA RMBS ECA CANG ICD OPRA IBM WISA CDEV JGPK LYB COG ECA SPDI SBOW PHX TGT NTR BRY HPQ URBN TELL

4
Midstates Petroleum in talks to buy some Sandridge assets

2018-08-16 worldoil
NEW YORK (Bloomberg) -- Midstates Petroleum Co. may soon walk away with at least some of SandRidge Energy Inc. after setting out to acquire all of it earlier this year.
SDOCQ SDRPQ MPO MPOYQ SDRXP SD SDRXQ

 
Midstates Petroleum Company, Inc. (MPO) CEO David Sambrooks on Q2 2018 Results - Earnings Call Transcript

2018-08-04 seekingalpha
Midstates Petroleum Company, Inc. (NYSE:MPO) Q2 2018 Results Earnings Conference Call August 3, 2018 8:30 AM ET
MPO MPOYQ

10
UPDATE 1-SandRidge draws interest from more bidders, including Midstates

2018-06-29 reuters
June 29 (Reuters) - SandRidge Energy Inc has been approached by 26 potential bidders for a buyout of the company or some of its assets, the U.S. shale oil producer said on Friday, days after activist investor Carl Icahn took control of its board.
SDOCQ SDRPQ MPO MPOYQ SDRXP SD SDRXQ

4
Icahn expected to speed push for SandRidge sale after board win

2018-06-20 worldoil
The activist investor’s win on Tuesday installs a board expected to strongly market a company many investors would like to see broken up or sold off, said David Beard, a Coker & Palmer Inc. analyst in New Orleans. While the Oklahoma City-based driller has already disclosed contacts with potential bidders, Icahn has labeled those efforts a “ sham.”
MPO MPOYQ

20
SandRidge Approached by 17 Suitors, Icahn says Not to Bid Soon

2018-06-15 rigzone
June 15 (Reuters) - SandRidge Energy Inc said on Friday it had been approached by 17 potential bidders for a buyout, including billionaire Carl Icahn who is fighting for control of the oil and gas producer's board.
SDOCQ SDRPQ MPO DVN TRI MRO MPOYQ BCEI SDRXP SD SDRXQ

19
SandRidge Says Approached by 17 Potential Buyers, Including Icahn

2018-06-15 rigzone
June 15 (Reuters) - SandRidge Energy Inc said on Friday it had been approached by 17 potential bidders for a buyout, including billionaire Carl Icahn who is fighting for control of the oil and gas producer's board.
SDOCQ SDRPQ MPO DVN MRO MPOYQ BCEI SDRXP SD SDRXQ

19
UPDATE 3-SandRidge says approached by 17 potential buyers, including Icahn

2018-06-15 reuters
(Reuters) - SandRidge Energy Inc (SD.N) said on Friday it had been approached by 17 potential bidders for a buyout, including billionaire Carl Icahn who is fighting for control of the oil and gas producer’s board.
SDOCQ SDRPQ MPO DVN MRO MPOYQ BCEI SDRXP SD SDRXQ

14
SandRidge says approached by 17 potential buyers, including Icahn

2018-06-15 channelnewsasia
REUTERS: SandRidge Energy Inc said on Friday it had been approached by 17 potential bidders for a buyout, including billionaire Carl Icahn who is fighting for control of the oil and gas producer's board.
SDOCQ SDRPQ MPO MPOYQ BCEI SDRXP SD SDRXQ

14
Carl Icahn to Push for Full Board Refresh at SandRidge - WSJ

2018-04-05 wsj
Carl Icahn intends to nominate a full slate of candidates to the board of SandRidge Energy Inc., SD -0.74% saying that the current board’s overseeing a strategic review “is likely to be value destructive.”
SDOCQ SDRPQ MPO MPOYQ BCEI SDRXP SD SDRXQ

14
Carl Icahn Will Nominate Full Sandridge Board Slate - Bloomberg

2018-04-05 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
SDOCQ SDRPQ MPO MPOYQ BCEI SDRXP SD SDRXQ

94
Oil & Gas Stock Roundup: Shell's Iraq Sale, Apache's North Sea Find & More

2018-03-27 zacks
It was a week where oil rebounded to levels not seen since January but natural gas futures settled down further.
ITOCY APA BRGYY RDS.B RDS.A TXN SDRPQ RDSB RDSA SD BMI COP BG BHI BRGXF SDOCQ ITOCF RYDBF MPO MPOYQ RYDAF SDRXP SDRXQ

14
For Some Wounded US Drillers, the Oil Rout Never Ended

2018-03-27 rigzone
(Bloomberg) -- More than a year after exiting bankruptcy, SandRidge Energy Inc. is stuck in stock-market purgatory.
SDOCQ UPL SDRPQ MPO UPLMQ MPOYQ BCEI SDRXP SD SDRXQ

8
For some wounded American drillers, the oil rout never ended

2018-03-27 worldoil
The oil and gas explorer has seen its stock sink 37% since October 2016, despite a restructuring that wiped out $4 billion in debt. Activist investor Carl Icahn is threatening a proxy fight, and last week SandRidge rejected a merger that would have valued the once $11-billion company at just $589 million.
UPL MPO UPLMQ MPOYQ BCEI

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 59804T100